Hemophilia A Concept

subject area of

• A Canadian survey of self-infusion practices in persons with haemophilia A  Academic Article
• A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada  Academic Article
• A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A  Academic Article
• A Practical Guide to the Management of the Fetus and Newborn With Hemophilia  Academic Article
• A brief survey of clinicians’ perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in haemophilia  Academic Article
• A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients  Academic Article
• A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients  Academic Article
• A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred  Academic Article
• A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates  Academic Article
• A pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia  Academic Article
• A preliminary application of a haemophilia value framework to emerging therapies in haemophilia  Academic Article
• A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose  Academic Article
• A study of variations in the reported haemophilia A prevalence around the world  Academic Article
• A survey of factor prophylaxis in the Canadian haemophilia A population  Academic Article
• A survey of patients with haemophilia to understand how they track product used at home  Academic Article
• A systematic review of definitions and reporting of bleeding outcome measures in haemophilia  Academic Article
• A therapeutic alternative for haemophiliacs with inhibitors  Academic Article
• AIDS in a patient with hemophilia receiving mainly cryoprecipitate.  Academic Article
• ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease  Academic Article
• ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease  Academic Article
• Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years  Academic Article
• Achieving the unimaginable: Health equity in haemophilia  Academic Article
• Acquired Hemophilia A  Academic Article
• Acquired Hemophilia A  Academic Article
• Acquired hemophilia masked by warfarin therapy  Academic Article
• Adherence with haemophilia treatments: a survey of haemophilia healthcare professionals in Canada  Academic Article
• Adjusted dose continuous infusion of factor VIII in patients with haemophilia A  Academic Article
• Adsorption of immunoglobulin G and anti-Factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes  Academic Article
• Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward  Academic Article
• Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners  Academic Article
• Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa  Academic Article
• Assessments of outcome in haemophilia – a patient perspective  Academic Article
• Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B  Academic Article
• BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial  Academic Article
• Bleeding disorders in neonates  Academic Article
• Bleeding time in hemophilia a: Potential mechanisms for prolongation  Academic Article
• Bone mineral density in haemophilia patients  Academic Article
• Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders  Academic Article
• Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?  Academic Article
• Can evidence harm? Certainly not hemophilia treatment and community  Academic Article
• Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT  Academic Article
• Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study)  Academic Article
• Cardiovascular disease prevalence and relevance in haemophilia: a scoping review  Academic Article
• Care models in the management of haemophilia: a systematic review  Academic Article
• Carrier detection in the hemophilias  Academic Article
• Carrier detection of haemophilia A using DNA markers in families with an isolated affected male  Academic Article
• Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families  Academic Article
• Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada.  Academic Article
• Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia  Academic Article
• Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules  Academic Article
• Central venous access device insertion and perioperative management of patients with severe haemophilia A  Academic Article
• Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company  Academic Article
• Characteristics of septic arthritis in human immunodeficiency virus- infected haemophiliacs versus other risk groups  Academic Article
• Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users  Academic Article
• Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?  Academic Article
• Clotting factor concentrate switching and inhibitor development in hemophilia A  Academic Article
• Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B  Academic Article
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Academic Article
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Academic Article
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Academic Article
• Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice  Academic Article
• Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population  Academic Article
• Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?  Academic Article
• Comparing bleed frequency and factor concentrate use between haemophilia A and B patients  Academic Article
• Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial  Academic Article
• Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia  Academic Article
• Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A  Academic Article
• Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders  Academic Article
• Concentrate‐related inhibitor risk: is a difference always real?  Academic Article
• Confusion around the official classification of arthropathy  Academic Article
• Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B  Conference Paper
• Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness  Academic Article
• Continuous infusion  Conference Paper
• Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience  Academic Article
• Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time  Academic Article
• Coping Style in Relation to the Consumption of Factor Concentrate in HIV-Infected Hemophiliacs during the Years after Their Infection Became Known  Academic Article
• Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH  Academic Article
• Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project  Academic Article
• Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden  Academic Article
• Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada  Academic Article
• DDAVP—The Multipotent Drug in Patients With Coagulopathies  Academic Article
• Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)  Academic Article
• Design and assessment of clinical trials on continuous infusion.  Conference Paper
• Developing a tracking system for coagulation factor concentrates in southern Ontario  Academic Article
• Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients  Academic Article
• Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup  Academic Article
• Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization  Conference Paper
• Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project  Academic Article
• Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors  Academic Article
• Diagnosis and treatment of intracranial hemorrhage in children with hemophilia  Academic Article
• Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment  Academic Article
• Different etiologies of acquired torticollis in childhood  Academic Article
• Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Academic Article
• Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Academic Article
• Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?  Academic Article
• Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.  Academic Article
• Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A  Academic Article
• Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.  Academic Article
• Effects of factor VIII concentrates on the immune system in hemophilic patients  Academic Article
• Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review  Academic Article
• Emicizumab state‐of‐the‐art update  Academic Article
• Ensuring maximum outcomes and benefits in comprehensive care for bleeding disorders through surveillance and data collection  Academic Article
• Epidural hemaoma in hemophilia: successful treatment.  Academic Article
• Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males  Academic Article
• Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies  Academic Article
• Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH  Academic Article
• Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor  Academic Article
• Evaluation of the sexual health in people living with hemophilia  Academic Article
• Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study  Academic Article
• Evidence about HUI and hemophilia in response to Young et al. “How well does the Canadian hemophilia outcomes‐kids' life assessment tool (CHO‐KLAT) measure the quality of life of boys with hemophilia?”  Academic Article
• Evidence of a disability paradox in patient‐reported outcomes in haemophilia  Academic Article
• Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU  Academic Article
• Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS)  Academic Article
• Experiences with continuous infusion of recombinant activated factor VII.  Conference Paper
• Exploring internet needs and use among adolescents with haemophilia: a website development project  Academic Article
• Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study  Academic Article
• Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment  Academic Article
• FALSE NEGATIVE RESULT BY THE WELLCOZYME ANTI-HIV ASSAY IN TESTING AN HIV POSITIVE HAEMOPHILIAC  Academic Article
• FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies  Academic Article
• Factor VIII Products and Inhibitors in Severe Hemophilia A  Academic Article
• Factor VIII concentrate for hemophilia: comparison of two heat-treated products.  Academic Article
• Factor VIII products and inhibitors in severe hemophilia A.  Academic Article
• Factor VIIa gets even bigger  Academic Article
• Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice  Academic Article
• Factors responsible for ADP-induced release reaction of human platelets  Article
• Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach  Academic Article
• Feasibility of Using Recombinant Factor VIIa in Continuous Infusion  Academic Article
• First analysis of 10‐year trends in national factor concentrates usage in haemophilia: data from CHARMS , the Canadian Hemophilia Assessment and Resource Management System  Academic Article
• First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study  Academic Article
• Gene Therapy for Hemophilia  Academic Article
• Gene Therapy for Hemophilia: Addressing the Coming Challenges of Affordability and Accessibility  Academic Article
• Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?  Academic Article
• Genotypes, phenotypes and whole genome sequence: Approaches from theMy Life Our Futurehaemophilia project  Academic Article
• Global data and haemophilia care trends: commentary  Academic Article
• HIV Infection in a Defined Population of Swedish Haemophiliacs  Academic Article
• HIV-serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs  Academic Article
• Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia  Academic Article
• Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics  Academic Article
• Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population  Academic Article
• Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.  Academic Article
• Haemophilia in a real-world setting: the value of clinical experience in data collection  Academic Article
• Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia  Academic Article
• Haemophilia prophylaxis: how can we justify the costs?  Academic Article
• Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements  Academic Article
• Handheld computers and paper diaries for documenting the use of factor concentrates used in haemophilia home therapy: a qualitative study  Academic Article
• Health status and health-related quality of life associated with hemophilia  Academic Article
• Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy  Academic Article
• Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders  Academic Article
• Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A  Academic Article
• Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.  Academic Article
• Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.  Academic Article
• Hemophilia in the 1990s: Principles of Management and Improved Access to Care  Academic Article
• Hepatitis C Virus-infected, HCV-RNA-negative Patients with Bleeding Disorders - Relationship to Age, HIV and Treatment  Academic Article
• Hepatitis C genotypes in Australian haemophilia patients  Academic Article
• Hepatitis E virus infection in hemophiliacs  Academic Article
• Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden  Academic Article
• Heterogeneity of information regarding inhibitors in the product monographs of antihaemophilic factors in North America  Academic Article
• Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains  Academic Article
• High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs  Academic Article
• High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance  Academic Article
• Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process  Academic Article
• Humanistic burden of problem joints for children and adults with haemophilia  Academic Article
• IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII  Academic Article
• Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts  Academic Article
• Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.  Academic Article
• Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B  Academic Article
• Immunodepletion of human plasma factor VIII  Academic Article
• Immunogenicity, efficacy and safety of Nuwiq^®(human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study  Academic Article
• Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up  Academic Article
• Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study  Academic Article
• Improving comprehensive care in the haemophilia community: building on the HERO Study  Academic Article
• Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.  Academic Article
• Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products  Academic Article
• Individualizing Factor Replacement Therapy in Severe Hemophilia  Academic Article
• Inhibitor development in haemophilia according to concentrate  Academic Article
• Inhibitor development in non-severe haemophilia across Europe  Academic Article
• Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression  Academic Article
• Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases  Academic Article
• Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors  Academic Article
• Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics  Academic Article
• Joint WFH-ISTH session: issues in clinical trial design  Academic Article
• Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more  Academic Article
• Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia  Academic Article
• Limited Protective Effect of the CCR5Δ32/CCR5Δ32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus  Academic Article
• Low Dose Prophylaxis vis-a-vis on-Demand Treatment Strategies for Hemophilia: A Cost Effective and Disability Attenuating Approach.  Academic Article
• Low prevalence of inhibitor antibodies in the Canadian haemophilia population  Academic Article
• Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada  Academic Article
• Major surgery seems not to influence HIV disease progression in haemophilia patients  Academic Article
• Management of bleeding disorders: basic science  Academic Article
• Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data  Academic Article
• Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa  Academic Article
• Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management  Academic Article
• Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH  Academic Article
• Monkey business for hemophilia management  Academic Article
• Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience  Academic Article
• Monocyte-macrophage (M-M) functions in asymptomatic hemophiliacs and supertransfused thalassemics.  Academic Article
• More on: are randomized clinical trials the only truth? Not always  Academic Article
• Mortality and causes of death in Italian persons with haemophilia, 1990-2007  Academic Article
• Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up  Academic Article
• Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates  Academic Article
• Multiple Joint Procedures in a Single Operative Session on Hemophilic Patients  Academic Article
• Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study  Academic Article
• Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran  Conference Paper
• Myositis ossificans in hemophilia  Academic Article
• NHF-McMaster Guideline on Care Models for Haemophilia Management  Academic Article
• Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series  Academic Article
• New developments in laboratory diagnosis and monitoring  Academic Article
• No Evidence for Vertical Transmission in Children Born to HIV Seropositive Male Haemophiliacs  Academic Article
• Nonviral Gene Therapy Approaches to Hemophilia  Academic Article
• Non‐severe haemophilia: Is it benign? – Insights from the PROBE study  Academic Article
• North American Study of Factor VIII Concentrate Potency  Academic Article
• Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate  Academic Article
• On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome  Academic Article
• Oral Corticosteroid Therapy as an Adjuvant Treatment for Acute Bleeding in Hemophilia Patients With High Titer Inhibitors  Academic Article
• Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care  Academic Article
• Orthotopic liver transplantation in a patient with combined hemophilia A and B  Academic Article
• Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders  Academic Article
• Outcomes indicators and processes in transitional care in adolescents with haemophilia: A Delphi survey of Canadian haemophilia care providers  Academic Article
• Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes  Academic Article
• Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF ‐PFM  Academic Article
• Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment  Academic Article
• Patients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study  Academic Article
• Patterns of joint damage in severe haemophilia A treated with prophylaxis  Academic Article
• Performance of recalibrated ReFacto^®laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto^®(B-domain deleted recombinant factor VIII)  Academic Article
• Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH  Academic Article
• Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study  Academic Article
• Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A  Academic Article
• Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium  Academic Article
• Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)  Academic Article
• Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation  Academic Article
• Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation  Academic Article
• Point-of-care ultrasonography in haemophilia care: Training and competency for muscular haematomas  Academic Article
• Prevalence of hepatitis C virus infection among patients with inherited bleeding disorders in Newfoundland.  Academic Article
• Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized  Academic Article
• Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature  Academic Article
• Psychological interventions for people with hemophilia  Academic Article
• Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire  Academic Article
• Psychosocial Self-Prognosis in Relation to Mortality and Morbidity in Hemophiliacs with HIV Infection  Academic Article
• Psychosocial aspects of haemophilia: a systematic review of methodologies and findings  Academic Article
• Pulmonary Hypertension in Hemophilia  Academic Article
• Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls  Academic Article
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review  Academic Article
• Recombinant Factor VIIa in Multiple Surgery  Academic Article
• Recombinant factor VIII concentrate  Academic Article
• Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors  Academic Article
• Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere-FRA(X)-DXS15-DXS52-F8C-telomere  Academic Article
• Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH  Academic Article
• Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group  Academic Article
• Redefining Disease? The Nosologic Implications of Molecular Genetic Knowledge  Academic Article
• Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A  Academic Article
• Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates  Academic Article
• Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice  Academic Article
• Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development  Academic Article
• Resolution of myositis ossificans in a hemophiliac.  Academic Article
• Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study  Academic Article
• Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature  Academic Article
• Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients  Conference Paper
• SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY  Academic Article
• Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting  Academic Article
• Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.  Academic Article
• Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers  Academic Article
• Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study  Academic Article
• Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study  Academic Article
• Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection  Academic Article
• Sonography for assessment of haemophilic arthropathy in children: a systematic protocol  Academic Article
• Suggestions for the management of factor VIII inhibitors  Academic Article
• Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy  Academic Article
• Survey of the Canadian hemophilia population.  Academic Article
• Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity  Academic Article
• Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics  Academic Article
• Switching patients in the age of long-acting recombinant products?  Academic Article
• Switching to extended half-life products in Canada - preliminary data  Academic Article
• THE TREATMENT OF HAEMOPHILIA A WITH ANTI‐HAEMOPHILIC FACTOR  Academic Article
• Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort  Academic Article
• Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study  Academic Article
• Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement  Academic Article
• Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database  Academic Article
• The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates  Academic Article
• The International Registry of Immune Tolerance: 1994 Update  Conference Paper
• The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype  Academic Article
• The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters  Academic Article
• The World Federation of Hemophilia Annual Global Survey 1999‐2018  Academic Article
• The current state of adverse event reporting in hemophilia  Academic Article
• The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study  Academic Article
• The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies  Academic Article
• The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A  Academic Article
• The establishment of murine blood outgrowth endothelial cells and observations relevant to gene therapy  Academic Article
• The factor VIII-independent activation of factor X by factors IXa and VII in plasma  Academic Article
• The haemophilia certification system in Canada.  Academic Article
• The importance of haemophilia treatment centre administrators in patient care  Academic Article
• The national haemophilia program standards, evaluation and oversight systems in the United States of America.  Academic Article
• The onerous task of comparing treatments in inhibitor patients  Academic Article
• The plasma concentration of activated protein C appears normal in patients with haemophilia  Academic Article
• The role of telemedicine in the delivery of health care in the COVID‐19 pandemic  Academic Article
• The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey  Academic Article
• The value of usability testing for Internet-based adolescent self-management interventions: “Managing Hemophilia Online”  Academic Article
• The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A  Academic Article
• Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A  Academic Article
• Thrombin generationin vitroin the presence of by-passing agents in siblings with severe haemophilia A  Academic Article
• Tissue factor microparticles and haemophilia  Academic Article
• Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1  Academic Article
• Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A  Academic Article
• Towards comprehensive care in transition for young people with haemophilia  Academic Article
• Transmission of HIV Infection to Heterosexual Partners but Not to Household Contacts of Seropositive Haemophiliacs  Academic Article
• Transmission of hepatitis C with pasteurised factor VIII  Academic Article
• Treatment decision‐making among Canadian youth with severe haemophilia: a qualitative approach  Academic Article
• Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme  Academic Article
• Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A  Academic Article
• Understanding FVIII/VWF complex - report from a symposium of XXIX WFH meeting 2010  Academic Article
• Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study  Academic Article
• Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A  Academic Article
• Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A  Academic Article
• Using pharmacokinetics to individualize hemophilia therapy  Academic Article
• Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders  Academic Article
• Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia  Academic Article
• Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders  Academic Article
• Validation of a composite score for clinical severity of hemophilia  Academic Article
• WFH – the cornerstone of global development: 45 years of progress  Academic Article
• What is a cure and how do we get there?  Academic Article
• What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia  Academic Article
• What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers  Academic Article
• World Federation of Hemophilia Gene Therapy Registry  Academic Article
• World Federation of Hemophilia: 50 years of advancing treatment for all  Academic Article
• World bleeding disorders registry: The pilot study  Academic Article
• [Centralized care is the basis of care programs for hemophilia patients].  Academic Article
• [Cure of hemophilia is approaching. Gene therapy is the hope].  Academic Article
• [Desmopressin--an effective agent in many hemorrhagic disorders].  Academic Article
• [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].  Academic Article